WallStSmart

BrightSpring Health Services, Inc. Common Stock (BTSG)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 382% more annual revenue ($65.77B vs $13.65B). MRK leads profitability with a 13.6% profit margin vs 2.3%. MRK trades at a lower P/E of 35.6x. BTSG earns a higher WallStSmart Score of 53/100 (C-).

BTSG

Buy

53

out of 100

Grade: C-

Growth: 8.7Profit: 5.5Value: 4.0Quality: 6.0
Piotroski: 5/9Altman Z: 2.59

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BTSG.

MRKSignificantly Overvalued (-62.3%)

Margin of Safety

-62.3%

Fair Value

$81.23

Current Price

$129.79

$48.56 premium

UndervaluedFair: $81.23Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BTSG2 strengths · Avg: 9.0/10
EPS GrowthGrowth
359.8%10/10

Earnings expanding 359.8% YoY

Revenue GrowthGrowth
25.6%8/10

Revenue surging 25.6% year-over-year

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$307.25B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

Areas to Watch

BTSG4 concerns · Avg: 2.8/10
Profit MarginProfitability
2.3%3/10

2.3% margin — thin

Operating MarginProfitability
3.4%3/10

Operating margin of 3.4%

Debt/EquityHealth
1.363/10

Elevated debt levels

P/E RatioValuation
90.1x2/10

Premium valuation, high expectations priced in

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
35.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : BTSG

The strongest argument for BTSG centers on EPS Growth, Revenue Growth. Revenue growth of 25.6% demonstrates continued momentum.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : BTSG

The primary concerns for BTSG are Profit Margin, Operating Margin, Debt/Equity. A P/E of 90.1x leaves little room for execution misses. Thin 2.3% margins leave little buffer for downturns.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Key Dynamics to Monitor

BTSG profiles as a growth stock while MRK is a value play — different risk/reward profiles.

BTSG carries more volatility with a beta of 1.79 — expect wider price swings.

BTSG is growing revenue faster at 25.6% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

BTSG scores higher overall (53/100 vs 50/100) and 25.6% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

BrightSpring Health Services, Inc. Common Stock

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

BrightSpring Health Services, Inc. (BTSG) is a leading provider of home and community-based health services, focusing on diverse patient populations, including individuals with intellectual and developmental disabilities and those in need of rehabilitation support. The company prioritizes personalized, high-quality care, facilitated by a dedicated and skilled workforce that significantly improves patient outcomes and quality of life. With robust investments in innovative technologies and a strong commitment to value-based care, BrightSpring is well-positioned to capitalize on growth opportunities within the dynamic healthcare landscape, highlighting its potential for sustainable, long-term success.

Visit Website →

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?